RATIONALE: The Ca(2+) sensitivity of the myofilaments is increased in hypertrophic cardiomyopathy and other heart diseases and may contribute to a higher risk for sudden cardiac death. Ca(2+) sensitization increases susceptibility to reentrant ventricular tachycardia in animal models, but the underlying mechanism is unknown. OBJECTIVE: To investigate how myofilament Ca(2+) sensitization creates reentrant arrhythmia susceptibility. METHODS AND RESULTS: Using hypertrophic cardiomyopathy mouse models (troponinT-I79N) and a Ca(2+) sensitizing drug (EMD57033), here we identify focal energy deprivation as a direct consequence of myofilament Ca(2+) sensitization. To detect ATP depletion and thus energy deprivation, we measured accumulation of dephosphorylated Connexin 43 (Cx43) isoform P0 and AMP kinase activation by Western blotting and immunostaining. No differences were detected between groups at baseline, but regional accumulation of Connexin 43 isoform P0 occurred within minutes in all Ca(2+)-sensitized hearts, in vivo after isoproterenol challenge and in isolated hearts after rapid pacing. Lucifer yellow dye spread demonstrated reduced gap junctional coupling in areas with Connexin 43 isoform P0 accumulation. Optical mapping revealed that selectively the transverse conduction velocity was slowed and anisotropy increased. Myofilament Ca(2+) desensitization with blebbistatin prevented focal energy deprivation, transverse conduction velocity slowing, and the reentrant ventricular arrhythmias. CONCLUSIONS: Myofilament Ca(2+) sensitization rapidly leads to focal energy deprivation and reduced intercellular coupling during conditions that raise arrhythmia susceptibility. This is a novel proarrhythmic mechanism that can increase arrhythmia susceptibility in structurally normal hearts within minutes and may, therefore, contribute to sudden cardiac death in diseases with increased myofilament Ca(2+) sensitivity.
RATIONALE: The Ca(2+) sensitivity of the myofilaments is increased in hypertrophic cardiomyopathy and other heart diseases and may contribute to a higher risk for sudden cardiac death. Ca(2+) sensitization increases susceptibility to reentrant ventricular tachycardia in animal models, but the underlying mechanism is unknown. OBJECTIVE: To investigate how myofilament Ca(2+) sensitization creates reentrant arrhythmia susceptibility. METHODS AND RESULTS: Using hypertrophic cardiomyopathymouse models (troponinT-I79N) and a Ca(2+) sensitizing drug (EMD57033), here we identify focal energy deprivation as a direct consequence of myofilament Ca(2+) sensitization. To detect ATP depletion and thus energy deprivation, we measured accumulation of dephosphorylated Connexin 43 (Cx43) isoform P0 and AMP kinase activation by Western blotting and immunostaining. No differences were detected between groups at baseline, but regional accumulation of Connexin 43 isoform P0 occurred within minutes in all Ca(2+)-sensitized hearts, in vivo after isoproterenol challenge and in isolated hearts after rapid pacing. Lucifer yellow dye spread demonstrated reduced gap junctional coupling in areas with Connexin 43 isoform P0 accumulation. Optical mapping revealed that selectively the transverse conduction velocity was slowed and anisotropy increased. Myofilament Ca(2+) desensitization with blebbistatin prevented focal energy deprivation, transverse conduction velocity slowing, and the reentrant ventricular arrhythmias. CONCLUSIONS: Myofilament Ca(2+) sensitization rapidly leads to focal energy deprivation and reduced intercellular coupling during conditions that raise arrhythmia susceptibility. This is a novel proarrhythmic mechanism that can increase arrhythmia susceptibility in structurally normal hearts within minutes and may, therefore, contribute to sudden cardiac death in diseases with increased myofilament Ca(2+) sensitivity.
Authors: Suzanne J Baron; Ji Li; Raymond R Russell; Dietbert Neumann; Edward J Miller; Roland Tuerk; Theo Wallimann; Rebecca L Hurley; Lee A Witters; Lawrence H Young Journal: Circ Res Date: 2005-01-13 Impact factor: 17.367
Authors: Norbert Frey; Klara Brixius; Robert H G Schwinger; Thomas Benis; Alex Karpowski; Hans P Lorenzen; Mark Luedde; Hugo A Katus; Wolfgang M Franz Journal: J Biol Chem Date: 2006-08-01 Impact factor: 5.157
Authors: Justin E Davies; Zachary I Whinnett; Darrel P Francis; Charlotte H Manisty; Jazmin Aguado-Sierra; Keith Willson; Rodney A Foale; Iqbal S Malik; Alun D Hughes; Kim H Parker; Jamil Mayet Journal: Circulation Date: 2006-04-03 Impact factor: 29.690
Authors: Monique C de Waard; Jolanda van der Velden; Virginie Bito; Semir Ozdemir; Liesbeth Biesmans; Nicky M Boontje; Dick H W Dekkers; Kees Schoonderwoerd; Hans C H Schuurbiers; Rini de Crom; Ger J M Stienen; Karin R Sipido; Jos M J Lamers; Dirk J Duncker Journal: Circ Res Date: 2007-03-08 Impact factor: 17.367
Authors: Karl Toischer; Wuqiang Zhu; Mark Hünlich; Belal A Mohamed; Sara Khadjeh; Sean P Reuter; Katrin Schäfer; Deepak Ramanujam; Stefan Engelhardt; Loren J Field; Gerd Hasenfuss Journal: J Clin Invest Date: 2017-10-30 Impact factor: 14.808
Authors: Jolanda van der Velden; Carolyn Y Ho; Jil C Tardiff; Iacopo Olivotto; Bjorn C Knollmann; Lucie Carrier Journal: Cardiovasc Res Date: 2015-01-28 Impact factor: 10.787
Authors: Frederik Flenner; Birgit Geertz; Silke Reischmann-Düsener; Florian Weinberger; Thomas Eschenhagen; Lucie Carrier; Felix W Friedrich Journal: J Physiol Date: 2017-02-07 Impact factor: 5.182
Authors: Farbod Sedaghat-Hamedani; Elham Kayvanpour; Oguz Firat Tugrul; Alan Lai; Ali Amr; Jan Haas; Tanja Proctor; Philipp Ehlermann; Katrin Jensen; Hugo A Katus; Benjamin Meder Journal: Clin Res Cardiol Date: 2017-08-24 Impact factor: 5.460